October 2009
Anavex Life Sciences Corp.
                                                 Disclaimer

The Presentation has been prepared...
Anavex History Summary
σ Current pipeline of products developed over seven-years via research collaborations involving
   ...
Biopharmaceutical Industry Summary
σ The global pharmaceutical market grew to US $ 712 billion in 2007 at a compound annua...
Company Highlights
σ   Anavex Life Sciences Corp. (www.anavex.com) is an emerging Biopharmaceutical Company. It is a
    g...
Sigmaceptor Platform: Anavex Product Candidates
ANAVEX's SIGMACEPTOR(TM)-N program involves the development of novel drugs...
ANAVEX CURRENT PIPELINE PORTFOLIO PROSPECTS
           Development Timeline and Costs 2009 - 2013

               COMPUND ...
Funding Requirements and Use Of Proceeds Breakdown To
                   September 2010

                                 ...
Business Objectives over 24-Months Sep. 2009-2011
SEPTEMBER 2009      SEPTEMBER 2010           SEPTEMBER 2011

PRE-IND in ...
Projected Anavex Post-Launch Turnover Breakdown
                          2015-2020
                                      ...
Alzheimer’s Disease
σ Currently 28 million patients worldwide, with another person afflicted every minute

σ By 2050 1 in ...
Co-development Deals In Alzheimer’s Disease Are Large
         Anavex In Talks To Reach That Goal
                        ...
A Competitor’s Historical Share Price Chart
Medivation (MDVN: NASDAQ) is in Phase III Clinical Trials with its Alzheimer’s...
Anavex’s Rich Oncology Pipeline

σ Oncology   (cancer) is a fast growing US$ 8bn market


σ ANAVEX   should have 3 compoun...
Oncology Companies Comparable to Anavex in 12 - 18 months
Achieve High Market Caps Even Without Alzheimer’s Compound
     ...
Recent Acquisitions Of Oncology (Cancer) Products
         Anavex In Talks To Sign Similar Type Of Deal
                  ...
Key Management
 Hervé de Kergrohen, MD, MBA, Chief Executive Officer and Director
 •   Dr. de Kergrohen has extensive expe...
International Board
 Hervé de Kergrohen, MD, MBA, Chief Executive Officer and Director
 • Dr. de Kergrohen has extensive e...
Scientific Advisory Board Of World-Renowned Experts
  Alexandre Vamvakides, PhD
  •   Chairman of Scientific Advisory Boar...
Stock Summary – As At August 14th, 2009
                          Stock Symbol         AVXL.OB
                   Shares O...
Anavex’s Three-Year Historical Trading Chart
                2007-2009
Anavex (AVXL:OB) will move up to the AMEX exchange ...
Upcoming SlideShare
Loading in …5
×

Anavex Corporate Presentation

11,255 views
11,922 views

Published on

Anavex, entrering clinical trials in Alzheimer and cancer

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
11,255
On SlideShare
0
From Embeds
0
Number of Embeds
1,743
Actions
Shares
0
Downloads
11
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Anavex Corporate Presentation

  1. 1. October 2009
  2. 2. Anavex Life Sciences Corp. Disclaimer The Presentation has been prepared by Anavex Life Sciences Corp. using its best efforts to realistically and factually present the information contained. However, subjective opinion, dependence upon factors outside Anavex Life Sciences Corp.’s control and outside information sources unavoidably dictate that Anavex Life Sciences Corp. cannot warrant the information contained to be exhaustive, complete or sufficient. In addition, many factors can affect us which could significantly alter the results intended by Anavex Life Sciences Corp., rendering the information/ projections in the Presentation unattainable or substantially altered. Therefore, interested Users should conduct their own assessment and consult with their own professional advisors prior to making any investment decisions. This Presentation does not constitute a prospectus or public offering for financing, and no guarantees are made or implied with regard to the success of Anavex Life Sciences Corp.’s proposed ventures. The Presentation is being disclosed to User for User’s discussion, review, and/or evaluation only. User also agrees not to trade in the securities of Anavex Life Sciences Corp. while in possession of any material information about Anavex Life Sciences Corp. that has not been publicly disclosed. User agrees to hold the Presentation, and all related information and discussions, in strict confidence, except that User may disclose the Presentation to a limited number of advisors and employees of the User to the extent necessary for User to adequately evaluate the Presentation. User warrants that any such employee shall be advised of the confidential nature of the Presentation before gaining access to the same and that no such advisor or employee shall use or disclose the Presentation except as specifically permitted by this Disclaimer. User agrees that Anavex Life Sciences Corp. reserves all rights in and to the Presentation. User agrees to return all originals and all copies of all materials related to Presentation to Anavex Life Sciences Corp. upon request or upon the conclusion of User’s review and evaluation of the Presentation thereof, whichever is earlier. Slide: 2
  3. 3. Anavex History Summary σ Current pipeline of products developed over seven-years via research collaborations involving Alexandre Vamvakides, PhD and other worldwide leaders in Sigma Receptors σ Focus on treatments for Alzheimer’s Disease and Cancer σ Reverse merger into OTCBB company January 2007 Slide: 3
  4. 4. Biopharmaceutical Industry Summary σ The global pharmaceutical market grew to US $ 712 billion in 2007 at a compound annual growth rate (CAGR) of 10.0% between 1999 and 2007. σ The leading therapy area by sales was the Central Nervous System (CNS) with 16.5% share. σ According to URCH Publishing, the global pharmaceutical market is forecasted to grow to $ 929 billion in 2012, an equivalent compound annual growth rate (CAGR) of 5.5% over the next 5-years. σ In addition to the revenues’ rapid growth, drug companies have enjoyed extremely high returns on investment capital in recent years as well as a favourable company survivorship rate compared with many other industries. σ According to IMS (Global healthcare advisor), annual sales for drugs that combat Alzheimer’s disease are projected to reach US$8 billion by 2012. Four of the seven Product Candidates Anavex have developed address diseases of the CNS with its lead candidate an Alzheimer's compound Anavex 2-73 soon to go into Human Clinical Trials Slide: 4
  5. 5. Company Highlights σ Anavex Life Sciences Corp. (www.anavex.com) is an emerging Biopharmaceutical Company. It is a global Company with headquarters in Geneva, Switzerland. It is engaged in the discovery and development of novel drugs which target the treatment of Cancer and Neurological Diseases of the Central Nervous System (CNS), such as Alzheimer's, Epilepsy and Depression. σ Anavex have a Scientific Advisory Board of world-renowned experts, a highly skilled Management Team and an International Board of Directors. σ Anavex has 7 product candidates in development for 8 disease indications. One of the products is in IND stage and six of them in Preclinical stage. The Company’s target is to launch Human Clinical Trials for 4 of its compounds (Alzheimer’s, Melanoma, Prostate and Epilepsy) by the beginning of 2010, while the other compounds will follow up. σ When comparing data with the world’s leading Alzheimer’s drug Donepezil (Eisai/Pfizer), Donepezil was active at a dose of 0.5mg/kg at least, Anavex 2-73 was fully active at 0.3 mg/kg and sometimes (for some aspects) even at 0.1 mg/kg. The lower dosage logically leads to lower toxicity indication. This finding alone makes Anavex 2-73, a strong candidate for Human Clinical Trials for Alzheimer's Disease. σ The Company has International Patents on all of its Product Candidates and has 35 new compounds in the early Pre-clinical stage of development. International Patents will be obtained for these as well as updates to Patents for existing product candidates. σ Potential sales of the Company’s products after launch are estimated at US$6 billion. Slide: 5
  6. 6. Sigmaceptor Platform: Anavex Product Candidates ANAVEX's SIGMACEPTOR(TM)-N program involves the development of novel drugs that target NEUROLOGICAL AND NEURODEGENERATIVE DISEASES, such as Alzheimer's disease, epilepsy, depression, pain and neuropathic pain. The company's lead candidates have shown strong evidence for anti-amnesic and neuroprotective properties in studies conducted to date. ANAVEX believes that mitochondrial dysfunction can be modulated via SIGMA RECEPTORS, a unique class of receptor molecules, to guard against oxidative stress. ANAVEX's SIGMACEPTOR(TM)-C program involves the development of novel drugs targeting CANCER. The company's lead candidates have shown strong evidence for selective pro-apoptotic, anti-metastatic and low toxicity properties in various types of solid cancers. ANAVEX 7-1037 has already demonstrated its ability to significantly delay the growth of cancerous tumours in patient-derived xenografts during advanced pre-clinical studies. Seven Anavex Product Candidates ANAVEX 3-97 MELANOMA ANAVEX 7-1037 PROSTATE ANAVEX 22-1068 PANCREAS ANAVEX 2-73 ALZHEIMERS / DIABETES ANAVEX19-144 EPILEPSY ANAVEX 1-41 ALZHEIMERS / DEPRESSION ANAVEX 10-90 NEUROPATHIC PAIN Slide: 6
  7. 7. ANAVEX CURRENT PIPELINE PORTFOLIO PROSPECTS Development Timeline and Costs 2009 - 2013 COMPUND YEAR 2009 2010 2011 2012 2013 ANAVEX 3-97 Cancer (Indic. Melanoma) Pre-clinical Phase II Phase II / III Phase III Phase III ANAVEX 7-1037 Cancer (Indic. Prostate) Pre-clinical Phase I Phase I / II Phase II / III Phase III ANAVEX 22-1068 Cancer (Indic. Pancreas) Pre-clinical Phase I Phase I / II Phase II / III Phase III ANAVEX 2-73 Alzheimer’s IND Phase I Phase II Phase II / III Phase III ANAVEX 2-73 Diabetic Degenerations Pre-clinical Pre-Clinical Pre-clinical IND / Phase I / II Phase II ANAVEX 19-144 Epilepsy Pre-clinical IND / Phase 1 Phase I Phase II Phase II / III ANAVEX 1-41 Alzheimer’s Pre-clinical IND Phase I Phase II Phase II / III ANAVEX 1-41 Depression Pre-clinical IND Phase I Phase II Phase II ANAVEX 10-90 Pain Pre-clinical Preclinical Pre-clinical IND / Phase I / II Phase II Anavex’s Total Estimated Annual R&D Costs (in US$ million) Year Total R&D Costs 2009 2010 2011 2012 2013 Total 2.8 8.8 24.5 44 62.5 142.6 Slide: 7
  8. 8. Funding Requirements and Use Of Proceeds Breakdown To September 2010 Anavex Requires USD$ 10.0 mil to move four of its product candidates into Phase I and one of its candidates into Phase II of development by September 2010. Of the USD$10.0 mil, 2.0 mil will be used for listing on the AMEX stock exchange and for general administration and development costs. The Company’s target is to launch Human Clinical Trials for four of its compounds (Alzheimer's Disease, Melanoma, Prostate Cancer and Epilepsy) by the beginning of 2010 while other compounds will follow.
  9. 9. Business Objectives over 24-Months Sep. 2009-2011 SEPTEMBER 2009 SEPTEMBER 2010 SEPTEMBER 2011 PRE-IND in Phase I in ALZHEIMER Phase II in ALZHEIMER ALZHEIMER Phase II in CANCER Phase II / III in CANCER PRE-IND in CANCER (Melanoma) and (Melanoma) and Phase I in and EPILEPSY IND / Phase I EPILEPSY EPILEPSY No PARTNERSHIP 1 PARTNERSHIP in ALZHEIMER and 2 1 PARTNERSHIP (outside PARTNERSHIPS outside Alzheimer) ALZHEIMER OTCBB Listing AMEX Listing NASDAQ Listing (current)
  10. 10. Projected Anavex Post-Launch Turnover Breakdown 2015-2020 Final No. Of Projected Compliance Total Expected Yearly Sales Total Patients At Initial Complied Patients Yearly After Current Patients Market Market Market Per-Year Therapy Launch in Compound Disease Stage (2009) Sales Launch 2009 (,000) CAGR % Time(,000) Share Share (,000) Cost ($) USD$,000 Cancer ANAVEX 3-97 MELANOMA Pre-Clinical 01/01/2016 630 5.00% 886 20.0% 50% 10.00% 88.6 5,000 443,237 Cancer ANAVEX 7-1037 PROSTATE Pre-Clinical 01/01/2018 2,200 1.55% 2,527 12.5% 65% 8.13% 205.3 3,000 615,867 Cancer ANAVEX 22-1068 PANCREAS Pre-Clinical 01/01/2015 180 3.00% 215 12.5% 50% 6.25% 13.4 18,000 241,796 ANAVEX 2-73 (Back- up ANAVEX 1-41) Alzheimer's IND 01/01/2017 17,000 3.23% 21,916 10.0% 50% 5.00% 1,095.8 1,600 1,753,282 Diabetic ANAVEX 2-73 Degeneration Pre-Clinical 01/01/2019 750 15.00% 3,034 20.0% 60% 12.00% 364.1 600 218,460 ANAVEX 19-144 Epilepsy Pre-Clinical 01/01/2018 6,300 0.71% 6,714 13.0% 80% 10.40% 698.3 1,200 837,931 ANAVEX 1-41 Depression Pre-Clinical 01/01/2019 88,000 1.90% 106,224 3.0% 60% 1.80% 1,912.0 600 1,147,224 Neuropathic ANAVEX 10-90 Pain Pre-Clinical 01/01/2020 160,000 1.40% 186,439 2.0% 50% 1.00% 1,864.4 400 745,757 Totals 275,060 327,956 6,242.0 6,003,553
  11. 11. Alzheimer’s Disease σ Currently 28 million patients worldwide, with another person afflicted every minute σ By 2050 1 in 85 persons worldwide will be living with the disease σ Four currently marketed meds all off patent within five-years 1. Aricept (donepezil hydrochloride) Eisai and co-marketed with Pfizer 2. Exelon (rivastigmine) Novartis Pharmaceuticals 3. Reminyl (galantamine) Co-developed by Shire Pharmaceuticals and the Janssen Research Foundation 4. Ebixa (memantine) Merz and marketed in Europe by Lundbeck σ Alzheimer’s Disease is a ‘must-invest’ area for Big-Pharma σ Only three early-stage, pure-play candidates available for Big-Pharma licensing σ Competitive environment remarkably favorable for ANAVEX σ Most other programs target mechanisms of action recently invalidated like anti-amyloid Slide: 11
  12. 12. Co-development Deals In Alzheimer’s Disease Are Large Anavex In Talks To Reach That Goal Mode of Company name Symbol Financing JV Status Action Phase date Vitae Pharmaceuticals Private Upfront $ 42m Boehringer Beta-secretase Pre-clinical 15/06/2009 Milestones $ 242m Ingelheim inhibitors Medivation MDVN Upfront $ 225m Pfizer Dimebon, II/III 03/09/2008 Milestones $ 725m mitochondrial effect Co-Mentis Private Upfront $ 100m Astellas Beta-secretase I 25/04/2008 (formerly Athenagen) Milestones $ 760m inhibitors and + nicotinic receptor discovery agonists Neurimmune Private $ 380m Biogen Idec Antibodies R&D 20/11/2007 Therapeutics EPIX Pharmaceuticals EPIX Upfront $ 35m GlaxoSK plc 5 HTA partial Discovery 12/12/2006 Milestones $ 1200m agonist program Idera Pharmaceuticals IDP Upfront 30m Merck & Co Toll-like receptor I 11/12/2006 Milestones $ 366m agonists AC Immune Private $ 300m Genentech Anti beta amyloid preclinical 06/12/2006 antibodies
  13. 13. A Competitor’s Historical Share Price Chart Medivation (MDVN: NASDAQ) is in Phase III Clinical Trials with its Alzheimer’s Drug, Dimebon (JV with Pfizer). The Chart below shows the spike in 2008 when it was still in Phase II, before the worldwide market crash. It traded at an all-time high of USD$ 33.80 on September 5th, 2008. Recovery from the crash has been steady with the Company closing at USD$27.63 October 8th. Slide: 13
  14. 14. Anavex’s Rich Oncology Pipeline σ Oncology (cancer) is a fast growing US$ 8bn market σ ANAVEX should have 3 compounds in the clinics and ready to partner in 18 months σ One compound could advance directly into Phase II σ ANAVEX will become an active target for Big Pharma: • Phase I or II data with novel compounds • Platform for further productivity in a new mechanism of action Slide: 14
  15. 15. Oncology Companies Comparable to Anavex in 12 - 18 months Achieve High Market Caps Even Without Alzheimer’s Compound Therapeutic Company Name Stage Market Cap Area Anavex Pre-IND $ 52m Oncology, CNS, Alzheimer’s Disease Alnylam Phase II $ 928m Oncology, others Ardea Phase II $ 295m Oncology, Gout, HIV Arqule Phase II $ 280m Oncology Array Phase II $ 175m Oncology, inflammation, metabolism Celldex Phase II $ 124m Oncology, infectious disease Dendreon Phase II-III $ 2.4bn Oncology * as at October 15, 2008 with data from Wm. Lowry Research and Yahoo Finance
  16. 16. Recent Acquisitions Of Oncology (Cancer) Products Anavex In Talks To Sign Similar Type Of Deal Therapeutic Company Name Product Acquirer Date Stage Upfront Milestones Area BiPar Sciences Sanofi-aventis 15/04/2009 Phase II $ 500m Oncology Incorporated Arana Cephalon, Inc. 27/02/2009 Phase II & $ 207m Oncology and Therapeutics preclinical inflammatory Limited Arius Research Roche 23/07/2008 Preclinical, $ 189m Oncology and immunology SGX Eli Lilly and Co 08/07/2008 Phase I & $ 64m Oncology Pharmaceuticals, Preclinica Inc. U3 Pharma AG Daiichi Sankyo 21/05/2008 Preclinical & $ 235m Oncology Co., Ltd. Research Piramed Pharma Roche 15/04/2008 Phase Ib $ 160m $ 175m Oncology and plus inflammatory preclinical Agensys, Inc. Astellas 27/11/2007 Phase Ib $ 387m $ 537m Oncology plus preclinical Adnexus Bristol-Myers 24/08/2007 Phase I $ 430m $ 505m Oncology Therapeutics Squibb Morphotek Eisai Inc. 22/03/2007 Phase I and $ 325m Oncology and preclinical Inflammatory and infectious * as of October 15, 2008 with data from Wm. Lowry Research and Yahoo Finance
  17. 17. Key Management Hervé de Kergrohen, MD, MBA, Chief Executive Officer and Director • Dr. de Kergrohen has extensive experience in building and transforming organizations, with more than 25 years in senior and executive management positions, including CEO, Chairman or Director roles with more than 12 companies in the United States and Europe. Alexandre Vamvakides, PhD, Scientific Founder, Chief Scientific Officer, Chairman of Scientific Advisory Board • More than 30 years in anti-neurodegenerative (anti-Alzheimer’s), anti-epileptic, anti- depressive research and development • Author of more than 80 published scientific papers • Institut national de la santé et de la recherche médicale (INSERM), University of Athens, Ciba-Geigy (now Novartis), sanofi-aventis • Track record of discovery and development of novel concepts in central nervous system (CNS), oncology and anti-inflammatory diseases Harvey Lalach, President, CFO, Secretary and Director • Various aspects of the securities industry for over 20 years • Focused on the operation and administration of numerous start-up US and Canadian public companies, serving in both director and officer capacities • Extensive experience in the management and governance of listed public companies Slide: 17
  18. 18. International Board Hervé de Kergrohen, MD, MBA, Chief Executive Officer and Director • Dr. de Kergrohen has extensive experience in building and transforming organizations, with more than 25 years in senior and executive management positions, including CEO, chairman or director roles with more than 12 companies in the United States and Europe. • Life Science Investment Advisor and Board Member/ High-level Consultant at Kergrohen & Associates. • Venture Partner at with CDC Innovation, an international venture capital firm with over 415-million Euros under its management. • Founder of BioData, a biotech conference held annually in Geneva. Cameron Durrant, MD, MBA, Chairman of the Board • Merck, GSK, Pharmacia, J&J (Worldwide Vice President, Global Strategic Marketing) • Former CEO, PediaMed; former CEO, Spherics • 2005 Ernst & Young healthcare ‘Entrepreneur of the Year’ • Co-founding Board member privately held oncology company (Bexion) Alison Ayers, MSc, Director • Worldwide Commercial Head for Oncology, Pfizer • More than 20 years of oncology-focused pharmaceutical industry experience • Business and product planning: Pharmacia, Merck, US Bioscience, BMS, Lederle Laboratories David L. Tousley, CPA, MBA, Director • President, COO and CFO at companies including airPharma, PediaMed Pharmaceuticals, AVAX Technologies and Pasteur, Merieux, Connaught (now sanofi-aventis) • Over $90MM in debt and equity financings • Leadership of key business development activities, including joint ventures, partnerships, acquisitions and divestitures in the US, Europe and Australia Harvey Lalach, President, CFO, Secretary and Director • Various aspects of the securities industry for over 20 years • Focused on the operation and administration of numerous start-up US and Canadian public companies, serving in both director and officer capacities • Extensive experience in the management and governance of listed public companies Slide: 18
  19. 19. Scientific Advisory Board Of World-Renowned Experts Alexandre Vamvakides, PhD • Chairman of Scientific Advisory Board, also company’s Scientific Founder and Chief Scientific Officer Jean-Jacques Bourguignon, PhD • 30 years experience in medicinal chemistry, including expertise in drug design and optimization as well as organic and physical chemistry • Research Director (CNRS) at the Faculty of Pharmacy, Strasbourg-Illkrich, France Tangui Maurice, PhD • 15 years in the field of neurosciences, including behavioral and molecular neuropharmacology, sigma receptors, neuropeptides, neurosteroids, neurotrophic factors, normal/pathological aging models for Alzheimer’s and related disorders, and behavioral phenotyping of rodent models • Former behavioral neuropharmacologist, INSERM U710, Montpellier Mark Smith, Ph.D., FRCPath • A leading researcher and professor in the Department of Pathology at Case Western Reserve University School of Medicine, and one of the world’s most cited researchers in the fields of Alzheimer’s disease, free radical biology and neuroscience and behavior • Executive Director of the American Aging Association and Editor-in-Chief of the Journal of Alzheimer’s Disease having authored over 600 peer-reviewed scientific manuscripts and book chapters • Scientific research, currently focused on investigating the pathological mechanisms underlying selective neuronal death in neurodegenerative diseases, notably Alzheimer’s disease Slide: 19
  20. 20. Stock Summary – As At August 14th, 2009 Stock Symbol AVXL.OB Shares Outstanding 20,746,761 Warrants Outstanding 986,147 Options Outstanding 3,075,000 Shares Fully Diluted 24,807,908 Market Capitalization $52.48MM % Held by Insiders 50% % Float 50% Funding History Summary • Research grants, self-financed by CSO (1998-2004) • $7.0MM pre-public by founding shareholder and affiliates (2004-2007) • $2.5MM equity and converted debt over $3.50/share (2007) • $1.6MM debt / $0.8MM equity (2008) • $818,000 debt / $2,254,143 equity (2009) Slide: 20
  21. 21. Anavex’s Three-Year Historical Trading Chart 2007-2009 Anavex (AVXL:OB) will move up to the AMEX exchange in Q1, 2010 as it enters into Human Clinical Trials for its Alzheimer's Compound Anavex 2-73. Slide: 21

×